Haythem Y. Ali, MD
The 2 biggest advancements in the treatment of patients with HER2-positive breast cancer in the last year were FDA approvals in the adjuvant setting, according to Haythem Y. Ali, MD.
In July 2017, the FDA approved neratinib (Nerlynx) for the extended adjuvant treatment of patients with early-stage, HER2-positive breast cancer following postoperative trastuzumab (Herceptin). This approval was based on data from the phase III ExteNET trial and the phase II CONTROL trial.
... to read the full story